金斯瑞(01548.HK)附屬傳奇生物(LEGN.US)配售ADS 籌3.5億美元
金斯瑞生物科技(01548.HK)公布,其非全資附屬傳奇生物(LEGN.US)向由投資顧問T. Rowe Price Associates, Inc.建議的基金或賬戶,配售約546.88萬股美國存託股份(ADS),相當於1,093.75萬股傳奇生物股份,每股ADS64美元(約502.4港元)。
傳奇生物預計從註冊直接發售中獲得所得款項總額3.5億美元(約27.48億港元),擬用作2025年第四季前計劃營運開支及資本支出。
完成後,公司於傳奇生物的持股量由51.36%攤薄至49.76%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.